Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity d

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, tod

DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

Technical indicators have turned bullish for the three stocks.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present

American Capital Management Inc. bought a new stake in DexCom, Inc. (NASDAQ: DXCM) in the undefined

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and keton

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation

Great Lakes Advisors LLC purchased a new position in shares of DexCom, Inc. (NASDAQ: DXCM) in the se

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Dan Deming discusses why he sees sideways action in the stock market continuing through next week, n

Aurora Investment Counsel bought a new stake in DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valu

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, whil

DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuatio

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but com

Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the pric

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cy

JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the pric

Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and rais

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and raises t

U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other g

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

Benchmark analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

BTIG analyst Marie Thibault maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target

DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billio

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus

The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health te

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada,

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating an

FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time G

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raise

https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr